B7 Proteins & Enzymes · Aggregation · Self-assembly

Amyloid & Protein Aggregation Platform

Aggregation quietly kills promising protein therapeutics and formulations. The platform screens stress conditions, maps aggregation kinetics and identifies stabilisation strategies. It also covers spider-silk self-assembly systems for biomedical and biomaterial applications.

Book a 30-minute discovery call Request the data package

Evidence: Method portfolio · report under NDA
Stage: Pilot-ready · licensing open
Indicative: € 8 000 – 60 000negotiable by scope and application

What the platform does

Aggregation is usually detected late and diagnosed poorly. The platform screens stress conditions systematically, follows aggregation kinetics rather than only endpoints, and identifies which stabilisation strategies actually shift the curve for your protein. It also covers engineered self-assembly — including spider-silk systems — where controlled assembly is the goal rather than the failure mode.

Two very different use cases

Preventing aggregation in a therapeutic or industrial protein, and exploiting assembly to build a biomaterial, use the same measurements pointed in opposite directions. Both are supported.

Applications

Therapeutic protein aggregation risk
Formulation stress screening
Neurodegeneration-related aggregation research
Self-assembling biomaterials

Assays & readouts available

Aggregation kinetics
Stress condition matrices (temperature, pH, ionic strength)
Light scattering and fluorescence probes
Stabilisation strategy ranking

Specification

Technology type	Aggregation and self-assembly characterisation
Research group	CIB — Centre for Interdisciplinary Biosciences
Evidence status	Pilot-ready capability; results generated for the partner under NDA
Typical pilot	Bioactivity/biophysics pilot, 4–8 weeks, or longer programme
Deliverables	Kinetic data, condition ranking, stabilisation recommendations
Engagement	Feasibility scan · pilot · licensing · co-development
Indicative price	€ 8 000 – 60 000, negotiable by scope and application

Aggregation research relevant to neurodegeneration is basic science. Nothing in this platform constitutes a diagnostic, therapeutic or clinical claim.

What happens next

Book a call or send an inquiry. Tell us the target, the application and the timeline.
We answer within three working days — including when the answer is that we cannot help.
NDA before disclosure, if you need one. Tick the box on the form.
Feasibility scan or pilot proposal with a defined scope, deliverable and price.

Book a 30-minute discovery call Send an inquiry

Common questions

How does an engagement start?

With a free 30-minute discovery call. We establish whether there is a fit and what the right next step is. Nothing is committed at that point.

Can we sign an NDA before we describe our project?

Yes. Tick the NDA box on the inquiry form and we arrange it before any disclosure.

Are the prices on this site binding?

No. They are indicative ranges so that you can size a project before contacting us. Final terms are negotiated per scope.

How quickly do you reply?

Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

What happens if you cannot help?

We say so, early, and where we can we point you to someone who can. A negative feasibility answer delivered quickly is a useful result.

Related in Proteins & Enzymes

B1Flagship platform

Protein engineering · Fibrinolytic variants

Staphylokinase Variant Screening Platform

Rank hundreds of variants without purifying each one. A cell-free expression platform scores staphylokinase variants by activity directly from unpurified reactions — built for engineering campaigns where variant numbers make conventional screening impractical.

Evidence: Publication reported 2026 · data package under NDA
Stage: Pilot-ready · co-development open
Indicative: € 12 000 – 60 000co-development quoted individually

View details Discuss this

Enzyme engineering · Directed evolution

Haloalkane Dehalogenase Engineering Platform

Carbon–halogen bond cleavage for remediation and industrial process chemistry. Directed evolution, ribosome display and catalytic optimisation applied to your substrate — relevant wherever a process generates or handles halogenated streams.

Evidence: Capability & method data under NDA
Stage: Pilot-ready · licensing open
Indicative: € 15 000 – 120 000negotiable by scope and application

View details Discuss this

Protein biophysics · Formulation support

Protein Stability & Formulation Platform

Know before you formulate. DSC, fluorescence probes and dynamic light scattering map thermodynamic and kinetic stability; buffer, salt and pH screening and aggregation risk profiling are run on your protein rather than on a generic prediction.

Evidence: Method portfolio · report under NDA
Stage: Pilot-ready
Indicative: € 8 000 – 50 000negotiable by scope and application

View details Discuss this

Tell us what you are trying to achieve.

A free 30-minute call establishes whether there is a fit and what the right next step is. Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

Book a 30-minute discovery call Send an inquiry instead